Red Light Therapy for Hair Growth — What Clinical Trials Show

Low-level laser therapy (LLLT) for hair growth is one of the few photobiomodulation applications that has achieved FDA clearance for a specific medical indication. Multiple randomised controlled trials demonstrate that red and near-infrared light at specific wavelengths can increase hair count, hair thickness, and hair density in both men and women with pattern hair loss.

This is not a fringe claim. The evidence base includes well-designed RCTs published in peer-reviewed dermatology journals, and LLLT devices are now recommended in clinical guidelines for androgenetic alopecia. But the results are not miraculous — understanding what the evidence actually shows, and what it does not, is essential for setting realistic expectations.

How red light stimulates hair growth

Hair follicles are among the most metabolically active structures in the human body. Each follicle cycles through growth (anagen), regression (catagen), and rest (telogen) phases. In androgenetic alopecia (AGA), the anagen phase progressively shortens and the follicle miniaturises — producing thinner, shorter, less pigmented hairs until the follicle ceases producing visible hair altogether.

Red and near-infrared light therapy appears to intervene in this process through several mechanisms:

Mitochondrial stimulation in follicular cells

The primary mechanism is the same as in other PBM applications: photon absorption by cytochrome c oxidase in the mitochondrial electron transport chain. In hair follicle cells — particularly dermal papilla cells and matrix keratinocytes — this increases ATP production, providing the energy needed for active hair growth (Avci et al., 2014, Lasers in Surgery and Medicine).

Prolonging anagen phase

LLLT appears to shift follicles from telogen (rest) back into anagen (growth) and to extend the duration of the anagen phase. Kim et al. (2013, Annals of Dermatology) demonstrated this in both animal models and human follicle organ cultures, showing that 660 nm light increased the proportion of follicles in anagen.

Increased blood flow to the scalp

Near-infrared light promotes nitric oxide release, which dilates blood vessels and improves microcirculation to the hair follicle. Given that miniaturised follicles in AGA show reduced blood supply, this may be a significant contributing mechanism (Lanzafame et al., 2014, Lasers in Surgery and Medicine).

Modulation of growth factors

PBM upregulates several growth factors relevant to hair biology, including vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and insulin-like growth factor 1 (IGF-1). It also modulates Wnt/beta-catenin signalling, a pathway critical for hair follicle cycling and regeneration (Buscone et al., 2017, Lasers in Surgery and Medicine).

Anti-inflammatory effects

Inflammation around hair follicles (perifollicular inflammation) is increasingly recognised as a contributor to AGA progression. PBM’s well-documented anti-inflammatory properties — reducing TNF-alpha, IL-1beta, and other pro-inflammatory mediators — may help create a more favourable microenvironment for hair growth.

The key clinical trials

Lanzafame et al., 2014 — Male pattern hair loss

This double-blind, sham device-controlled RCT is one of the most cited studies in the field. Lanzafame et al. (2014, Lasers in Surgery and Medicine) randomised 44 males with Norwood-Hamilton IIIa to V pattern hair loss to receive either 655 nm laser therapy (via a helmet device) or sham treatment every other day for 16 weeks.

Results:

• Active treatment group: 39% increase in hair count at 16 weeks
• Sham group: no significant change
• The difference was statistically significant (p<0.001)

The study used a laser helmet delivering 655 nm light at approximately 67 J/cm2 per session. Treatment was self-administered at home every other day for 25 minutes.

Lanzafame et al., 2014 — Female pattern hair loss

In a parallel study with the same design, Lanzafame et al. examined 47 women with Ludwig-Savin I-II pattern hair loss. The results were similarly positive:

Results:

• Active treatment group: 37% increase in hair count at 16 weeks
• Sham group: no significant change
• Again statistically significant (p<0.001)

These two studies are notable for their rigorous sham-controlled design (the sham device looked identical but delivered no therapeutic light) and the clinically meaningful magnitude of the effect.

Jimenez et al., 2014 — HairMax LaserComb trials

Jimenez et al. (2014, American Journal of Clinical Dermatology) reported pooled results from four double-blind, sham-controlled RCTs conducted across multiple US sites, evaluating the HairMax LaserComb (655 nm, 9-beam and 12-beam models).

Results across 225 subjects (128 male, 97 female):

• Male subjects: mean increase of 20.2-25.7 hair counts per cm2 (depending on device model) versus decreases in sham groups
• Female subjects: mean increase of 20.6-20.7 hair counts per cm2 versus minimal change in sham groups
• All comparisons statistically significant (p<0.001)

These trials formed the basis for the HairMax LaserComb’s FDA 510(k) clearance for hair growth promotion.

Kim et al., 2013 — Mechanism and clinical study

Kim et al. (2013, Annals of Dermatology) conducted both a mechanistic study (human hair follicle organ culture) and a clinical pilot. In the organ culture, 660 nm light significantly increased hair shaft elongation rate compared to untreated controls. In the clinical component, 660 nm LED treatment increased hair density in patients with alopecia.

Friedman and Friedman, 2017 — Systematic review

Friedman and Friedman (2017, Journal of the American Academy of Dermatology) systematically reviewed 11 clinical studies of LLLT for AGA and concluded that “the current body of evidence supports the use of LLLT for the treatment of AGA in both men and women.” They noted that most successful studies used wavelengths between 630 nm and 670 nm, with treatment durations of 8-26 weeks.

Afifi et al., 2017 — Meta-analysis

The most rigorous quantitative summary is the meta-analysis by Afifi et al. (2017, Lasers in Surgery and Medicine), which pooled data from 11 RCTs comprising 680 patients. The meta-analysis found:

• Significantly increased hair count in LLLT-treated patients versus controls (mean difference: 17.66 hairs per cm2, 95% CI: 10.31-25.01)
• The effect was consistent across male and female subjects
• Studies using 655 nm showed the most consistent results

Wavelength evidence: 650 nm vs 830 nm

The vast majority of positive clinical trials have used wavelengths in the red spectrum, specifically 630-670 nm. The dominant wavelength in the literature is 655 nm, largely because the HairMax LaserComb (655 nm) was the device used in the most trials.

Red wavelengths (630-670 nm)

• 655 nm: Most clinical evidence (Lanzafame 2014, Jimenez 2014, multiple HairMax trials)
• 660 nm: Positive results in Kim 2013 and several smaller studies
• 630 nm: Limited but positive data in some earlier studies

Red wavelengths at 650-660 nm penetrate approximately 2-3 mm into tissue, which is sufficient to reach the hair bulb in the dermis. The hair follicle bulb sits at approximately 2-4 mm depth, well within the penetration range of red light.

Near-infrared wavelengths (810-850 nm)

Near-infrared wavelengths penetrate deeper (3-5+ mm) and reach the follicle and surrounding vasculature. However, the clinical evidence for NIR in hair growth is significantly thinner than for red wavelengths.

Some recent devices combine 650-660 nm with 810-850 nm, theorising that the dual-wavelength approach provides both superficial follicular stimulation and deeper vascular effects. This is physiologically plausible but not yet supported by head-to-head comparative trials.

The 830 nm question

A small number of studies have examined 830 nm for hair growth, with mixed results. The theoretical basis is sound — improved deep tissue circulation, enhanced nutrient delivery to the follicle — but the absorption by cytochrome c oxidase at 830 nm is lower than at 660 nm. Whether this matters clinically remains uncertain.

Current recommendation: Based on the weight of clinical evidence, 650-660 nm remains the best-supported wavelength for hair growth. If a device offers dual wavelengths (red + NIR), this is likely a net positive but should not be considered essential.

Device landscape: caps, helmets, and combs

LLLT hair growth devices fall into three broad categories:

Laser combs / brushes

The original consumer LLLT hair device format. The HairMax LaserComb was the first to receive FDA 510(k) clearance.

Advantages: Lower cost; active combing action may improve light delivery to the scalp between hairs Disadvantages: Requires manual movement across the scalp; treatment uniformity depends on user technique; lower total diode count typically means less coverage per session

Laser caps / helmets

Hands-free devices worn on the head, containing arrays of laser diodes and/or LEDs.

Advantages: Hands-free operation; uniform coverage of the treatment area; more consistent dosing Disadvantages: Higher cost (typically £300-£1,500+); some models use LEDs rather than laser diodes (which may deliver lower irradiance per diode); coverage limited to the cap’s geometry

Notable devices include the iRestore, Capillus, Theradome, and HairMax LaserBand.

LED panels and handheld devices

General-purpose red light therapy panels can be used for scalp treatment by positioning the panel near the head. This is the least studied approach for hair growth specifically, but the physics is sound if the wavelength and dose are appropriate.

Advantages: Multi-purpose device (skin, pain, etc.); often higher total power output Disadvantages: Not ergonomically designed for scalp treatment; harder to ensure consistent coverage; treatment position can be awkward

What to look for in a hair growth device

• Wavelength: 650-660 nm is the best-supported choice
• Power density: Higher irradiance means shorter treatment times. Look for devices specifying irradiance at the scalp surface (mW/cm2), not just total wattage
• Diode count and coverage: More diodes generally means more uniform coverage. For a full-scalp device, 100+ diodes is typical; 200+ is better
• FDA clearance: Several devices have FDA 510(k) clearance specifically for hair growth promotion. This is not a guarantee of superiority, but it indicates that clinical data was submitted and reviewed
• Laser vs LED: Both can work, but laser diodes deliver more coherent, focused light. Most positive clinical trials used laser diodes, though LED-based devices are increasingly common

Realistic timeline expectations

Setting correct expectations is critical. Hair growth is slow — follicle cycling takes months, and visible results require patience.

What the clinical trials show

• 4 weeks: No visible changes expected. Follicles may be transitioning from telogen to anagen, but this is not yet visible to the naked eye
• 8-12 weeks: Some studies report initial measurable increases in hair count by this point, though the changes may not be visually obvious
• 16 weeks (4 months): This is the primary endpoint in most clinical trials. The Lanzafame 2014 studies showed 37-39% increases in hair count at 16 weeks
• 24-26 weeks (6 months): Extended treatment often produces further improvement. Jimenez 2014 used a 26-week endpoint with continued gains
• 12+ months: Long-term maintenance data is limited, but sustained use appears necessary to maintain results

Critical point: consistency matters

The positive trials all required consistent, regular use — typically every day or every other day. Sporadic use is unlikely to produce meaningful results. This is analogous to minoxidil: the treatment works, but only if you actually use it as directed.

What you should not expect

• Regrowth of completely bald areas: LLLT works by stimulating existing follicles. Follicles that have been completely destroyed (e.g., in advanced scarring alopecia or long-standing complete baldness) will not respond
• Results equivalent to hair transplantation: LLLT produces thicker, denser hair from existing follicles, not new follicles
• Overnight transformation: Even positive responders typically need 4-6 months to see meaningful visual improvement
• Universal response: Like all hair loss treatments, some individuals respond better than others. Response rates in clinical trials range from 60-80% for measurable improvement

Combining LLLT with other treatments

LLLT + minoxidil

The combination of LLLT and topical minoxidil is particularly interesting because the two treatments work through different mechanisms. Minoxidil is a vasodilator that also stimulates prostaglandin and VEGF production in follicles, whilst LLLT acts primarily through mitochondrial stimulation.

Esmat et al. (2017, Photodermatology, Photoimmunology & Photomedicine) compared LLLT alone, minoxidil alone, and LLLT + minoxidil in female pattern hair loss. The combination group showed significantly greater improvement in hair density than either treatment alone.

This synergistic potential makes biological sense: LLLT increases cellular energy and growth factor production, whilst minoxidil promotes vascular supply and prolongs anagen. The treatments are complementary rather than redundant.

LLLT + finasteride

Finasteride (and its more potent relative, dutasteride) reduces DHT — the androgen primarily responsible for follicle miniaturisation in AGA. LLLT does not directly address hormonal pathways, making the combination theoretically additive.

Clinical data specifically on the LLLT + finasteride combination is limited, but dermatologists commonly recommend the combination in practice. The rationale is straightforward: finasteride slows or stops the hormonal driver of hair loss, whilst LLLT actively stimulates growth from the existing follicle population.

LLLT + PRP (platelet-rich plasma)

Platelet-rich plasma injections deliver concentrated growth factors directly to the scalp. Some clinics offer LLLT as an adjunct to PRP therapy, and early evidence suggests potential synergy, though controlled trials of the specific combination are few.

LLLT + microneedling

Derma rolling or microneedling of the scalp has shown independent evidence for hair growth (Dhurat et al., 2013, International Journal of Trichology). The combination with LLLT is increasingly popular in clinical practice, though direct comparison trials are pending.

Alopecia areata

Alopecia areata (AA) is an autoimmune condition in which the immune system attacks hair follicles, causing patchy hair loss. The evidence for LLLT in AA is less robust than for AGA but shows some promise.

Yamazaki et al. (2003, Keio Journal of Medicine) reported that a 655 nm laser treatment promoted hair regrowth in alopecia areata patients in a small case series. The mechanism is likely immunomodulatory — reducing the T-cell-mediated attack on follicles — combined with direct follicular stimulation.

Several case reports and small studies have shown benefit, but no large RCTs have been conducted specifically for AA. The condition’s natural tendency toward spontaneous remission also complicates interpretation of uncontrolled data.

Current assessment: LLLT may be a useful adjunct for alopecia areata, particularly in patients who wish to avoid or reduce topical immunosuppressants, but the evidence is insufficient to recommend it as a primary treatment. Patients with AA should work with a dermatologist.

Deep dive: Red light therapy for alopecia areata

Safety

LLLT for hair growth has an excellent safety profile. Across all the major RCTs, adverse events were rare and minor:

• Scalp warmth or tingling during treatment — common but benign
• Transient shedding — some users report a brief increase in shedding during the first 2-4 weeks. This may represent telogen follicles being shed as they transition back to anagen (similar to the “minoxidil shed”). It is typically self-limiting
• Headache — rare; usually related to device weight or fit rather than the light itself
• Dry scalp — occasionally reported; easily managed with scalp moisturisers

No serious adverse events have been reported in the published literature. LLLT does not cause hair loss, does not damage existing hair, and does not increase skin cancer risk (the wavelengths used are non-ionising and non-UV).

Contraindications:

• Active scalp malignancy — avoid irradiating known or suspected skin cancers
• Photosensitising medications — exercise caution, though UV-related photosensitivity is not directly relevant to red/NIR wavelengths
• Open scalp wounds — allow to heal before treatment

The scalp health connection

Beyond direct follicular stimulation, LLLT may improve overall scalp health in ways that indirectly support hair growth:

• Reduced scalp inflammation — chronic low-grade inflammation (often invisible) contributes to follicle miniaturisation
• Improved sebaceous function — balanced sebum production supports the follicular microenvironment
• Enhanced scalp circulation — improved blood flow delivers nutrients and removes metabolic waste products from the follicular unit
• Collagen support — the extracellular matrix around follicles plays a role in anchoring and supporting hair growth

For scalp-specific protocols and considerations, see our scalp health guide.

The bottom line

Red light therapy for hair growth is one of the better-supported PBM applications. Multiple sham-controlled RCTs consistently demonstrate 20-40% increases in hair count at wavelengths of 650-660 nm over 16-26 weeks. The therapy has FDA clearance, is recommended in clinical guidelines for androgenetic alopecia, and has an outstanding safety profile.

The caveats are equally clear: results require consistent, long-term use; LLLT works on miniaturised follicles rather than dead ones; response rates are not 100%; and expectations should be calibrated to “meaningful improvement” rather than “full restoration.” For best results, consider combining LLLT with established treatments (minoxidil, finasteride) under dermatological supervision.

For device recommendations, see our best red light therapy devices guide. For deeper evidence reviews on specific conditions, explore the guides linked throughout this page.

References

• Afifi L, Maranda EL, et al. (2017). Low-level laser therapy as a treatment for androgenetic alopecia: a systematic review and meta-analysis. Lasers in Surgery and Medicine, 49(1), 27-39.
• Avci P, Gupta GK, et al. (2014). Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers in Surgery and Medicine, 46(2), 144-151.
• Buscone S, Mardaryev AN, et al. (2017). A new path in defining light parameters for hair growth: discovery and modulation of photoreceptors in human hair follicle. Lasers in Surgery and Medicine, 49(7), 705-718.
• Dhurat R, Sukesh M, et al. (2013). A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia. International Journal of Trichology, 5(1), 6-11.
• Esmat SM, Hegazy RA, et al. (2017). Low level light-minoxidil 5% combination therapy versus either modality alone in management of female patterned hair loss. Photodermatology, Photoimmunology & Photomedicine, 33(3), 167-174.
• Friedman S, Friedman J (2017). Low-level light therapy for androgenetic alopecia: a comprehensive review. Journal of the American Academy of Dermatology, 76(6), AB239.
• Jimenez JJ, Wikramanayake TC, et al. (2014). Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss. American Journal of Clinical Dermatology, 15(2), 115-127.
• Kim H, Choi JW, et al. (2013). Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial. Dermatologic Surgery, 39(8), 1177-1183.
• Lanzafame RJ, Blanche RR, et al. (2014). The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine, 46(8), 601-607.
• Yamazaki M, Miura Y, et al. (2003). Linear polarized infrared irradiation using Super Lizer is an effective treatment for multiple-type alopecia areata. International Journal of Dermatology, 42(9), 738-740.